ArticleActa scientific neurology2025
Dopaminergic Homeostatic Therapy (DHT
Article in Acta scientific neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
In spite of the ongoing exquisite work of a multitude of researchers worldwide including governmental institutions like the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and for example in the United States the FDA Medication Assisted Therapy (MAT) embracing Opioid Replacement Therapy (ORT) in 2022, 111,000 people prematurely died from opioid induced overdose. It is estimated that if treatment stays as usual by 2025 the death rate will increase to 165,00.Therefore, we are encouraging the scientific and clinical community to at least consider our "out of the box" thinking whereby we are proposing a new paradigm shift involving the " dopaminergic homeostatic modeling approach and Genetic screening to early identify preaddiction. In this novel approach following detoxification from for example powerful opioids, the patient is administered the validated RDSQ29 to access potential psychological profiling of Reward Deficiency Syndrome (RDS); obtain a cheek cell sample of the patient and perform genetic screening utilizing the Genetic Addiction Risk Severity (GARS); analyze mRNA to identify specific protein deficits/surfeits based on the measured reward genes involved in the Brain Reward Cascade (BRC); produce a customized pro-dopamine regulator (KB220) guided by GARS resulting polymorphisms; objectively employ the mRNA profiling assessment every week during the treatment phase to determine improvement; each treatment program could add on at their choice, for example, cognitive behavioral therapy, brain spotting, trauma therapy, electrotherapy (h-wave device to reduce pain, subluxation repair etc.) mindfulness, exercise, neuromodulation (PrTMS) amongst other modalities. The utilization of this model could prove beneficial to both substance and non-substance behavioral addictions (e. g. gaming). WC261 .
Indexed as
Identifiers
40896766PMC12396177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.